Enumeral Biomedical Holdings Inc fka ENUMQ

[DeltaWarrior]

Have you guys seen the board of directors here? Pretty impressive. Here are a few

Board of Directors

John J. Rydzewski
Executive Chairman of the Board of Directors and Co-Founder

John has been Executive Chairman since October 2011. He has significant life sciences industry experience as an institutional investor, investment banker and corporate director. Before joining Enumeral, John was managing director of Christofferson, Robb & Co., an investment firm where he monetized life-sciences intellectual property covering large and small molecule therapeutics from July 2006 to September 2011. His banking career included partnership responsibilities at Benedetto, Gartland & Co., an investment bank serving corporate and institutional clients, and officer positions in the merchant banking and healthcare specialty finance units of Kidder, Peabody & Co. and Dean Witter Reynolds. Prior to banking, John was a manager in the Bankruptcy Services Group of Price Waterhouse & Co., and he held positions in industry. He continues to serve as a director of several healthcare companies, including Vision-Sciences, Inc., and he is Co-Chairman of the Board of Advisors of the RAND Corporation’s health policy research unit. John received an M.B.A. and a B.S. in economics with honors from The Wharton School of the University of Pennsylvania.

Paul J. Sekhri
President, Chief Executive Officer and Director, Lycera

Mr. Sekhri is an accomplished industry executive, with more than 25 years of experience in life sciences strategy, corporate development and corporate finance, having served in senior leadership positions at several pharmaceutical companies. He is currently President and Chief Executive Officer of Lycera, and he also serves on its board of directors. Prior to joining Lycera, Mr. Sekhri was Senior Vice President, Integrated Care at Sanofi, and before that, he served as Group Executive Vice President, Global Business Development and Chief Strategy Officer at Teva Pharmaceutical Industries. Prior to this, Mr. Sekhri was Operating Partner and Head, Biotech Operations Group at TPG Biotech, where he was responsible for a portfolio of more than 50 life science firms. Previously, Mr. Sekhri was founder, President and Chief Executive Officer of Cerimon Pharmaceuticals, and before Cerimon, he was President and Chief Business Officer of Ariad Pharmaceuticals. He also held senior positions at Novartis, including Senior Vice President and Head, Global Search and Evaluation and M&A. Mr. Sekhri is also a director of Veeva Systems and has served as a director on numerous private and public company boards, including KAI Pharmaceuticals, Intercept Pharmaceuticals, Macrogenics, PatientSafe Solutions and Tandem Diabetes, and as a board advisor to IMS Health. He serves on the Board of Trustees for the non-profit Cancer Research Institute and on the Industry Advisory Boards of the Michael J. Fox Foundation, the TB Alliance and the Tectonic Theatre Project. Mr. Sekhri received a B.S. from the University of Maryland and completed postgraduate studies in clinical anatomy and neuroscience at the University of Maryland, School of Medicine.

http://investor.enumeral.com/phoenix.zhtml?c=253923&p=irol-govBoard